{
  "abstract": "Background The carbon footprint of asthma care in the UK is largely driven by metered-dose inhalers (MDIs). National policy encourages switching to dry powder inhalers (DPIs), which offer similar outcomes with significantly lower environmental impact. However, limited general practice capacity constrains opportunities for structured face-to-face medicines optimisation. Eclipse, a population health platform, offers a scalable solution to identify eligible patients and deliver targeted, digital-first interventions.Aims To evaluate the feasibility and patient engagement of a digital-first, population health-led approach to inhaler optimisation, supporting low-risk asthma patients to switch from Fostair 100/6 MDI to Fobumix Easyhaler DPI.Methods Eligible patients were identified using the Eclipse population health platform across 15 consenting practices in LLR ICB. Inclusion criteria were patients aged ≥18, coded with asthma, and prescribed Fostair 100/6 MDI. Exclusions included respiratory specialist care, a respiratory admission in the past 12 months, care home residency, or palliative/dementia codes.Patients were contacted centrally via SMS linking to a tailored information page and questionnaire assessing willingness to switch and baseline Asthma Control Test (ACT) score. Non-responders were followed up by telephone.Based on responses and ACT scores, patients were triaged within Eclipse for remote or in-practice follow-up. Those opting to switch were referred to their community pharmacy for New Medicine Service follow-up.Results Of 709 eligible patients, 689 (97.2%) successfully received an SMS. Among these, 412 accessed the digital information page, and 123 completed the questionnaire online. A further 441 completed it via telephone, resulting in 564 total responses. Of these, 281 (49.8%) opted to switch, 50 (8.9%) requested more information, and 206 (36.5%) declined. Demographic breakdown is presented in table 1.Abstract P290 Table 1Demographic Breakdown of Patients Engaged in the Digital-First Inhaler Optimisation PilotConclusions This pilot demonstrates that a digital-first approach to inhaler optimisation is feasible and well accepted, with telephone hub support playing a key role in maximising patient engagement. The high response rate, particularly through follow-up calls, underscores the value of combining digital outreach with personalised support. Strong uptake and willingness to switch highlight the model’s potential for scalable implementation across primary care. It supports environmentally sustainable prescribing in line with NHS Net Zero priorities, while preserving clinical safety and patient choice.",
  "authors": [
    {
      "affiliations": [
        "Prescribing Services Ltd, Norwich, UK"
      ],
      "name": "SA Brown"
    },
    {
      "affiliations": [
        "University Hospitals of Leicester NHS Trust, Leicester, UK"
      ],
      "name": "AC Murphy"
    },
    {
      "affiliations": [
        "Prescribing Services Ltd, Norwich, UK"
      ],
      "name": "CE Morris"
    },
    {
      "affiliations": [
        "Leicester Leicestershire and Rutland Integrated Care Board, Leicester, UK"
      ],
      "name": "D Gokal"
    }
  ],
  "title": "P290 Feasibility of a digital-first approach to inhaler optimisation in asthma care: supporting net zero NHS goals",
  "uid": "1f8431b5-e4d3-52da-a2eb-402704d7e497"
}